Palbociclib in Patients With Ovarian Cancer With
Publication Title
JCO Precis Oncol
Document Type
Article
Publication Date
7-1-2026
Keywords
Humans; Female; Piperazines; Ovarian Neoplasms; Pyridines; Registries; Middle Aged; Aged; Cyclin-Dependent Kinase Inhibitor p16; Adult; Antineoplastic Agents; washington; swedish; swedish cancer
Abstract
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) with
METHODS: Eligible patients had advanced OC, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with
RESULTS: Twenty-eight patients were enrolled from February 2017 to April 2023, and all had OC with a
CONCLUSION: Palbociclib met the prespecified criteria to declare a signal of activity in patients with OC and
Area of Special Interest
Cancer
Area of Special Interest
Women & Children
Specialty/Research Institute
Oncology
Specialty/Research Institute
Obstetrics & Gynecology
Specialty/Research Institute
Pharmacy
DOI
10.1200/PO-26-00456
